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Abstract
Background: This study investigated cause of death, mortality rates and explored if baseline characteristics were
associated with risk of death in patients with alcohol use disorder alone or poly-substance use disorders.
Methods: This was a prospective, longitudinal study of patients followed for 19 years after entering specialized
treatment for substance use disorders. At baseline 291 patients (mean age 38.3 years, standard deviation 11.4
years, 72% male) with high psychiatric co-morbidity were recruited; 130 (45%) had lifetime alcohol use disorder
alone, while 161 (55%) had poly-substance use disorders. Time and causes of death were gathered from the Norwegian
Cause of Death Registry. Lifetime psychiatric symptom disorders and substance use disorders at baseline were measured
with The Composite International Diagnostic Interview and personality disorders at baseline were measured with The
Millon Clinical Multiaxial Inventory II.
Results: Patients with alcohol use disorder alone more often died from somatic diseases (58% versus 28%, p = 0.004) and
more seldom from overdoses (9% versus 33%, p = 0.002) compared with patients with poly-substance use disorders. The
crude mortality rate per 100 person year was 2.2 (95% confidence interval: 1.8–2.7), and the standardized
mortality rate was 3.8 (95% confidence interval: 3.2–4.6) in the entire cohort during 19 years after entering
treatment. Having lifetime affective disorder at baseline was associated with lower risk of death (Hazard Ratio
0.58, 95% confidence interval: 0.37–0.91). Older age was associated to increased risk of death among men
(p < 0.001) and non-significantly among patients with poly-substance use (p = 0.057). The difference in
association between age and risk of death was significantly different between men and women (p = 0.011) and
patients with alcohol use disorder alone and poly-substance use disorders (p = 0.041).
Conclusions: Patients with alcohol use disorder alone died more often from somatic disease than patients
with poly-substance use disorders, and all subgroups of patients had an increased risk of death compared with
the general population. Men with long-lasting substance use disorders are a priority group to approach with
directed preventive measures for somatic health before they reach 50 years of age.
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Background
All mental disorders are associated with an increased
risk of premature mortality compared with the general
population, and substance use disorder (SUD) has the
highest mortality rates [1, 2]. A report on drug-related
mortality in nine European countries found that the crude
mortality rate (CMR) per 100 person years (PY) was 1.42
(95% confidence interval [CI]: 1.37–1.47) [3]. A global re-
view on mortality from illicit use of opiates reported
the CMR per 100 PY to be 2.09 (95% CI: 1.93–2.26),
with overdose being the most common cause of
death, and the standardized mortality ratio (SMR) was
14.66 (95% CI: 12.82–16.50) [4]. SMR compares the
deaths observed to the number of deaths expected
based on age and sex at a given time in the general
population. Opiate overdose mortality has increased
dramatically in several parts of the world during the
latest decades [5–7]. A review of alcohol use showed
that the relative risk of death in clinical samples with alco-
hol use disorder (AUD) was 3.38 (95% CI: 2.98–3.84) for
men and 4.57 (95% CI: 3.86–5.42) for women compared
with the general population [8]. Mortality rates in patients
treated for the first time for AUD are lower than in other
clinical populations of patients with AUD [9, 10], indicat-
ing that increased severity of AUD increases risk of death.
Patients with AUD have increased risk of death from car-
diovascular, digestive, respiratory and endocrine diseases,
cancer, mental disorders, suicide, and injuries [11]. There
is less research on mortality related to the use of sub-
stances other than opiates and alcohol, but a national
register study of all patients receiving treatment for
SUDs in Denmark found SMRs for principal cannabis
use of 4.9 (95% CI: 4.2–5.8), principal cocaine use of
6.4 (CI: 3.9–10.0), and principal amphetamine use of
6.0 (CI: 4.2–8.3) [12]. Research on mortality associated
with SUDs typically reports that men have a higher CMR
but lower SMR than women, younger people have a lower
CMR but higher SMR than older people, and SMRs are
higher in clinical cohorts than in more general popula-
tions [3, 4, 13–15]. Both CMR and SMR convey informa-
tion necessary to understanding mortality, and the
described differences in these rates are related to life ex-
pectancy in subgroups of the general population.
There are high levels of co-morbidity between SUDs
and other mental disorders in both general and clinical
populations [16, 17]. Mortality rates in patients with men-
tal disorders are higher among those with a co-morbid
SUD than those without an SUD [18, 19]. Few longitu-
dinal studies of the mortality of patients with SUDs focus
on the effect of co-morbid mental disorders. A study of
patients in treatment programmes for SUDs in England
showed that poly-substance use and anxiety increased the
risk of death [20]. In a cohort of patients with SUDs in
Sweden in which 59% were poly-substance abusers at first
admission, regular use of opiates or barbiturates and neur-
osis increased the risk of premature death, while cannabis
and psychosis decreased the risk [21]. There is a lack of
research on mortality in heterogeneous clinical cohorts or
comparing mortality in persons with AUD alone with per-
sons with poly-SUDs.
To improve treatment and preventive measures to re-
duce mortality, we need nuanced knowledge of the risk
of death, and from what causes and at which times, in
various subgroups of people with SUDs [4, 11]. In the
present study we examined mortality over 19 years in a
heterogeneous cohort of patients with AUD alone or
poly-SUDs and high psychiatric co-morbidity. Our aims
were to investigate: (1) characteristics of deceased pa-
tients and principal causes of death; (2) CMRs and
SMRs after entering treatment for SUDs; and (3) explore
whether any baseline characteristics are associated with
the risk of death in patients with AUD alone and those
with poly-SUDs.
Methods
Design
The present design was a prospective, longitudinal study
of a naturalistic cohort of patients with SUDs followed
for 19 years after entering specialized treatment for
SUDs in public facilities in two counties in eastern
Norway in 1997 and 1998. The cross sectional study at
baseline aimed to explore the prevalence of mental dis-
orders in the cohort. Prospective follow-up studies in
2004 and 2015/2016 aimed to explore prognosis and
risk-factors for different substance use and mental health
outcomes, and mortality.
Sample
At baseline, 291 patients from three outpatient (42%)
and six inpatient (58%) units for specialized treatment of
SUDs, owned or founded by the county councils of Hed-
mark or Oppland, were recruited. The inpatient units
had various treatment profiles according to only alcohol
use disorder (AUD) versus other SUDs or both, gender
divided treatment, being a therapeutic community, and
estimated length of treatment varied from 6 weeks to 18
months. The patients in the inpatient units had been re-
ferred from outpatient units. To be included in the
study, the subjects had to remain in the inpatient unit
for at least two weeks, or complete at least three consul-
tations in the outpatient units. Sampling, subjects and
methods at baseline have been described more exten-
sively elsewhere [22, 23]. Compared with a national
sample (n = 5000) of patients in facilities for special-
ized treatment for SUD in Norway in the same period,
our sample was skewed toward having older patients
with a longer duration of SUD and a higher frequency
of AUD [22].
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Measurements
Norwegian Cause of Death Registry: National identity
numbers for all patients (n = 291) were merged with data
from the Norwegian Cause of Death Registry. This pro-
vided dates of death until 31 December 2016, and causes of
death with medical diagnoses from death certificates (one
principal cause-of-death diagnosis, and up to seven under-
lying diagnoses, based on the World Health Organization
International Classification of Diseases-10 [ICD-10] [24]).
The cause of death of deceased patients was categorized
into ‘overdose’, ‘somatic’, ‘traumatic’, and ‘other’ from the
principal cause-of-death diagnoses. The reference popula-
tion for calculating SMRs included all residents in Norway
aged 25–84 in 2008. Annual number of all-cause deaths in
gender-stratified five-year age groups were obtained from
the Norwegian Institute of Public Health [25], and annual
population figures in the age groups 25–84 in 2008 were
obtained from Statistics Norway [26].
Baseline
The Composite International Diagnostic Interview (CIDI),
Norwegian computer version - a structured personal psy-
chiatric interview based on Diagnostic and Statistical Man-
ual of Mental Disorders, 4th Edition (DSM-IV) criteria -
and the corresponding non-hierarchical diagnoses in the
ICD-10 [27] were used for lifetime psychiatric symptom
disorders and SUDs. Four patients did not complete all sec-
tions on affective disorders in the CIDI, and eight did not
complete all sections on anxiety disorders. The Millon Clin-
ical Multiaxial Inventory II (MCMI-II) - a self-report psy-
chiatric diagnostic (DSM-III-R) inventory [28] - was used
to measure current personality disorders. Personality dis-
order diagnoses were assigned using a base-rate score of 85
or higher. The MCMI-II was not completed by 27 patients.
The Norwegian National Client Assessment form [29], was
used to provide information on socio-demographics and
treatment history.
Statistical analysis
Differences between participants with AUD alone and
those with poly-SUDs at baseline, between living and de-
ceased participants and between deceased participants
with AUD alone and deceased participants with poly-SUDs
at baseline were assessed using a χ2-test and independent
samples t test. Separate psychiatric disorders were clustered
into lifetime affective disorders (bipolar disorder, major de-
pressive disorder and dysthymia), lifetime anxiety disorders
(social phobia, agoraphobia, panic disorder, specific phobia,
obsessive compulsive disorder, and post-traumatic stress
disorder), and personality disorder (all personality disorders
in MCMI-II). CMR was calculated as the number of
all-cause deaths per 100 PY, and subgroups were compared
by incidence rate ratios (IRRs). SMRs were calculated for
all-cause deaths in the entire cohort, and by sex and age
groups based on national death rates by sex and age (five--
year cohorts) in the middle of the study period (year 2008).
All rates and ratios were reported with 95% CIs. Data were
described by means and SDs or frequencies and percent-
ages, as appropriate.
Bivariate and multiple Cox regression models assessing
factors associated with mortality were estimated for par-
ticipants with complete data collection (n = 254 (37 partic-
ipants were excluded from these models because of
missing data on CIDI and/or MCMI-II)). To perform the
analysis stratified by having AUD alone or poly-SUDs at
baseline, the multiple Cox regression model contained in-
teractions between AUD alone or poly-SUDs and the
other covariates. Interactions between age and sex, age
and affective disorder, age and first onset of an SUD be-
fore the age of 18 years, and sex and first onset of an SUD
before the age of 18 years were also assessed. The model
was reduced by applying Akaike’s Information Criterion
(AIC); covariates and interactions between covariates were
omitted if the AIC decreased. Models also contained a
random intercept for the treatment unit, adjusting for
possible within-unit correlations. The proportional haz-
ards assumption was tested and satisfied for all Cox
models. The results are presented as hazard ratios (HRs)
and CIs. For statistical analysis, STATA 15 (StataCorp
LLC) and SAS version 9.4 were employed.
Results
At baseline the cohort (n = 291) had a mean age of 38.3
years (standard deviation [SD] 11.4 years) and 72% were
male (Table 1). The baseline prevalence of lifetime anx-
iety disorder was 82%, 63% had a lifetime affective dis-
order, and the mean number of lifetime psychiatric
symptom disorders (not including SUDs) was 3.6. The
mean number of personality disorders at baseline was
2.7, while 28% had no personality disorder.
Among the recruited patients, 45% had lifetime AUD
alone, while 55% had poly-SUDs. This latter group had
an average of 3.6 lifetime SUDs (the term ‘poly-SUDs’ is
not entirely accurate, as 18 patients had only one other
lifetime SUD besides AUD: six had only opiate, six had
only cannabis, four had only sedative, and two had only
stimulant use disorder). Patients with AUD alone was
more often men, older, more often married or cohabit-
ant, more often had completed upper secondary school
or higher, more often had fulltime ordinary work, more
seldom had lifetime anxiety disorders, had fewer lifetime
psychiatric symptom disorders (not including SUDs),
more seldom had personality disorders, more seldom
had onset of first SUD before age 18 years of age and
were older at onset first SUD compared with patients
with poly-SUDs. Among the patients with poly-SUDs,
53% had lifetime opioid dependence, 49% lifetime stimu-
lant dependence, 50% lifetime sedative, hypnotic, or
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anxiolytic dependence, 41% lifetime cannabis depend-
ence, and 65% lifetime alcohol dependence.
Characteristics of deceased patients and principal causes
of death
Among the 291 patients entering treatment, 102 (35%)
were deceased approximately 19 years later (mean age at
death 54 years, SD 12 years), comprising 20 women (24%,
mean age at death 48 years, SD 11 years) and 82 men
(39%, mean age at death 56 years, SD 11 years). As dis-
played in Table 1, the deceased were more often men,
older, more seldom had lifetime affective disorders, had
fewer SUDs, more seldom had onset of first SUD before
age 18 years of age, were older at onset first SUD and
more often had AUD alone compared with living patients.
Among the patients with AUD alone, 51% were de-
ceased (mean age at death 59 years, SD 11 years), and 36
(22%) of the patients with poly-SUDs were deceased
(mean age at death 47 years, SD 11 years). Bivariate com-
parisons showed that the deceased with AUD only were
more often males, older, less likely to have lifetime
affective disorder, less likely to have lifetime anxiety
disorder, had fewer lifetime psychiatric symptom disor-
ders (not including SUDs), less likely to have experi-
enced the first onset of an SUD before 18 years of age
and were older at first onset SUD compared with de-
ceased patients with poly-SUDs.
In the total cohort, 48 (47%) had somatic disease, 12
(12%) traumatic death, and 18 (18%) overdose as the prin-
cipal cause of death (Table 2). More patients with AUD
alone died of somatic diseases (58% versus 28%, p = 0.004)
and fewer of overdose (9% versus 33%, p = 0.002) com-
pared with participants with poly-SUDs at baseline.
CMRs and SMRs after entering treatment for SUDs
As displayed in Table 3, in the entire cohort, the CMR per
100 PY was 2.2. Men had a higher CMR than women, with
an IRR of 1.8 (95% CI 1.1–3.0, p = 0.009), and younger pa-
tients had a lower CMR than older patients. Patients with
AUD alone had a higher CMR than those with poly-SUDs,
with an IRR of 2.6 (95% CI 1.7–4.1, p < 0.001). The SMR
for the entire cohort was 3.8. Women had an SMR of 5.2,
and males 3.6. The SMR for patients with AUD alone at
baseline was 3.4, while patients with poly-SUDs at baseline
Table 2 Principal cause of death retrieved from the Norwegian Cause of Death Registry over 19 years after entering treatment for
SUDs for the deceased (n = 102)
Total cohort
102 deceased
AUD alone
66 deceased
Poly-SUDs
36 deceased
pa
Somatic disease n (%) 48 (47) 38 (58) 10 (28) 0.004
Cancer n 16 14 2
Alcoholic liver disease (ICD-10 F70.0–F70.4) n 7 4 3
Heart/coronary disease n 7 7 –
Lung n 8 6 2
Others (only one participant per disease) n 10 7 3
Traumatic death n (%) 12 (12) 7 (11) 5 (14) 0.623
Accidents n 7 4 3
Suicide n 3 2 1
Homicide n 2 1 1
Overdose n (%) 18 (18) 6 (9) 12 (33) 0.002
Heroin n 7 1 6
Methadone n 5 2 3
‘Other’ opiods n 1 – 1
Alcohol n 2 2 –
Unspecified n 3 1 2
Other n (%) 24 (24) 15 (23) 9 (25) 0.796
AUD (ICD-10, F10)b n 15 11 4
Opioid use disorder (ICD-10, F11)b n 4 1 3
No diagnosis n 3 2 1
Sudden death (ICD-10, R960) n 2 1 1
ap-value, χ2-test comparison of causes of death between deceased participants with AUD alone at baseline compared with deceased participants with poly-SUDs
at baseline
bRegistered as AUD or opioid use disorder as principal cause of death in the Norwegian Cause of Death Registry. Under optimal registering practice, most of these
deaths should probably have been reported as somatic disease as principal cause of death
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had an SMR of 5.2. Not shown in Table 1 are patients who
died between the ages of 25 and 39 years (n = 15), who had
an SMR of 14.3 (95% CI 8.3–23.1); between 40 and 49 years
(n = 19), who had an SMR of 6.4 (95% CI 4.0–9.8); between
50 and 59 years (n = 32), who had an SMR of 5.9 (95% CI
4.1–8.3); and above 60 years (n = 36), who had an SMR of
2.1 (95% CI 1.5–2.9).
Baseline characteristics associated with risk of death in
patients with AUD alone and poly-SUDs
Table 4 displays results from a Cox regression analysis
assessing the association between baseline characteristics
and risk of death over 19 years after entering treatment for
SUDs. In bivariate models, age and AUD alone were associ-
ated with a higher risk of death, while having a lifetime
affective disorder and experiencing the first onset of an SUD
before the age of 18 years were associated with lower risk of
death (all p < 0.05). In the multiple model, having a lifetime
affective disorder (HR 0.58, 95% CI 0.37–0.91) was associ-
ated with lower risk of death. There were three interactions
left in the AIC-reduced multiple model, between age and
sex, age and first SUD onset before 18 years of age, and age
and AUD alone. For each one-year increase in age, the risk
of death increased by 6% in women (p= 0.057) and 12% in
men (p < 0.001), with risk being overall significantly different
between women and men (p= 0.011 for interaction). Explor-
ing the interaction term further revealed that the risk of
death is not significantly different between men and women
in younger patients, but from an age of about 50 years on-
wards, men have significantly higher risk of death than
women. In those with poly-SUDs increasing age was slightly
but not significantly associated with higher risk for death,
while the association was more or less stable in those with
AUD alone. The risk was overall significantly different be-
tween those with AUD alone and patients with poly-SUDs
(p= 0.042 for interaction). Patients up to about age of 35
years with AUD alone had higher risk of death than those
with poly-SUDs, with no differences between groups among
patients older than 35 years according to exploratory ana-
lysis of the interaction term. There were no significant
differences in the association between age and risk for
death among those with first SUD onset before the age of
18 years and age of 18 years or older, even though the
interaction was not eliminated from the model by AIC.
Discussion
In the present cohort, patients with AUD alone died
more often from somatic disease and more seldom from
overdose than patients with poly-SUDs. More than 2%
Table 3 All-cause deaths, crude mortality rate (CMR) per 100
person years (PY), and standardized mortality ratio (SMR) in the
cohort (n = 291) and subgroups over the 19 years after entering
treatment for SUDs
Deaths (%) Mortality rate per
100 PY (95% CI)
Standardized
mortality ratio
(95% CI)
Total cohort 102 (35) 2.2 (1.8–2.7) 3.8 (3.2–4.6)
Sex
Male 82 (39) 2.5 (2.1–3.2) 3.6 (2.9–4.5)
Female 20 (24) 1.4 (0.9–2.2) 5.2 (3.3–7.9)
Age at baseline
Under 30 years 11 (16) 0.9 (0.5–1.6)
30–39 years 25 (26) 1.6 (1.1–2.3)
40–49 years 32 (48) 3.1 (2.2–4.4)
Over 50 years 34 (61) 4.6 (3.3–6.4)
AUD alone at baseline
AUD alone 66 (51) 3.5 (2.8–4.5) 3.4 (2.6–4.2)
Poly-SUDs 36 (22) 1.3 (1.0–1.8) 5.2 (3.7–7.2)
Table 4 Cox regression analysis for risk of death over the 19
years after entering treatment for SUDs, n = 254 (cases with
missing data for at least one covariate were excluded)
Model 1a Model 2b
Bivariate
HR (95% CI)
Multiple, AIC
reduced
HR (95% CI)
Demographics
Sex, male (female – ref.) 1.50 (0.87–2.57) 1.12 (1.07–1.17)c ***
Age 1.06 (1.04–1.08)*** 1.06 (1.00–1.73)d
Mental health
Affective disorder
(no affective disorder – ref)
0.56 (0.37–0.87)** 0.58 (0.37–0.91)*
Anxiety disorder
(no anxiety disorder – ref)
0.83 (0.49–1.41)
Number of psychiatric
symptom disorders
(except SUDs)
0.95 (0.87–1.03)
Personality disorder
(no personality
disorder – ref)
1.00 (0.63–1.60)
Substance use
First SUD onset before
the age of 18 years
(above 18 years – ref.)c
0.58 (0.37–0.93)* 1.01 (0.96–1.07)c
AUD alone
(poly-SUDs – ref.)c
2.67 (1.67–4.24)*** 1.00 (0.96–1.05)c
* p < 0.05, ** p < 0.01, *** p < 0.001
aBivariate analysis of risk of death by 31 December 2016, adjusted for
inter-unit differences
bMultiple model for risk of death by 31 December 2016, stratified by having
AUD alone at baseline, adjusted for inter-unit differences. Stratification was
performed by estimating the model containing interactions between all
variables and AUD alone, and in addition to interactions between age and sex,
age and affective disorder, age and first SUD onset before the age of 18 years,
and sex and first SUD onset before the age of 18 years. The model was
reduced by applying the AIC, leaving three interactions in the model: age and
sex, age and first SUD onset before 18 years of age, and age and AUD alone
cHR for 1-year change in age
dHR for 1-year change in age in reference groups (female sex, first SUD onset
at 18 or more years, poly-SUDs)
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died annually through the 19-year observation period,
and all examined subgroups of patients had an increased
risk of death compared with the general population. In a
multiple analysis, we found that lifetime affective dis-
order at baseline was associated with a decreased risk of
death, while age and sex interact in predicting risk of
death. Older age was associated to increased risk of
death among men and non-significantly among patients
with poly-substance use. The difference in association
between age and risk of death was significantly different
between men and women and patients with alcohol use
alone and poly-substance use disorders.
As expected [4, 11], the principal causes of death in
patients with AUD alone were mainly somatic dis-
eases, and overdose was the most common principal
cause of death in patients with poly-SUDs. This dif-
ference is important to acknowledge and have clinical
implications because death from overdose or somatic
causes requires different preventive approaches. Pa-
tients with long-lasting SUDs need better access to
screening and treatment to reduce premature mortal-
ity from somatic causes, but this seems to receive less
systematic efforts compared to overdose prevention.
Several effective large-scale strategies for decreasing
death by overdose exist; e.g. opioid maintenance treat-
ment (OMT) [4], education about high-risk situations
or combinations of substances, means of intake, and
prevention with naloxone [30, 31]. For patients with
opiate use disorder OMT decrease somatic morbidity [32];
however patients in OMT also need improved somatic
health care to reduce premature mortality further [33]. Pa-
tients with SUDs also have other shared risk factors for pre-
mature mortality from somatic causes, which we have not
addressed in this study, and will probably benefit from
more indirect preventive measures for mortality, such as
adequate treatment for SUDs and mental disorders, smok-
ing cessation, exercise, and healthier nutrition.
Our findings for CMRs and SMRs by age group and sex
are similar to those found by other Norwegian [33–36]
and international studies [3, 4, 8] of mortality in patients
with SUDs. These results are however influenced by a se-
lection bias in that younger patients with poly-SUDs at
high risk of mortality from overdose or traumatic causes
were under-represented. The average age at baseline was
38 years, which means that the participants who entered
this study had already survived SUDs for a long time.
Somewhat counterintuitive, we found that having a life-
time affective disorder was associated with a decreased
risk of death, crudely adjusted for other factors. We have
no knowledge of studies indicating that affective disorders
decrease the risk of death in patients with SUDs, although
psychosis in combination with cannabis use disorder has
been reported to decrease the risk of death [21]. This may
be an effect of selection bias as the patients with AUD
alone had less lifetime affective disorders at baseline com-
pared to those with poly-SUDs, and many of the deceased
were older patients with AUD alone. Both men and
women with SUDs had, as expected, an increased risk
of death with increasing age, but men had a signifi-
cantly higher risk of death than women from an age
of 50 years onwards. This can have clinical implica-
tions for preventing premature death because we
know most of these men die from somatic causes.
Unlike some other studies [20, 21] we did not find
mental disorders to be associated with an increased
risk of death. These negative findings may also be re-
lated to sample characteristics.
Limitations
The present study has limitations that must be con-
sidered when interpreting the results. We have a
baseline selection bias in that younger patients at
high risk of death from overdose or traumatic causes
are under-represented. The cohort should ideally be
larger and the study may be underpowered regarding
the multiple Cox models, which increase the chance of
type-II statistical error [37]. Also, the multiple analysis is
only crudely adjusted as persons with SUDs have several
relevant risk factors for premature mortality which we
have not investigated, e.g. smoking, unhealthy lifestyle,
and genetic factors. Our finding that psychiatric disorders
do not increase the risk of mortality may be an effect of
high baseline prevalence, which makes differences difficult
to detect (i.e. Berkson’s fallacy [38]). SUDs and psychiatric
co-morbidities at baseline may have changed for several
patients and influenced their mortality over the 19-year
study period. There can also be problems in measuring
lifetime mental disorders at baseline in temporal proxim-
ity to substance abuse, and there can be differences be-
tween the diagnoses reached via structured diagnostic
interviews, as we used, compared with those by clinical
experts, who likely set fewer diagnoses [39].
The main strengths of the study were the 19-year
study period, the heterogeneous clinical cohort with
long-term problematic substance use, and the thorough
diagnostic investigation with structured personal inter-
views at baseline. Despite possible limitations, this
study provides useful and unique longitudinal data re-
garding the mortality of patients with AUD alone or
poly-SUDs and may help to direct future research and
treatment interventions.
Conclusions
This study confirms and extends knowledge that patients
with SUDs have substantially higher risk of death than the
general population, and that type of SUD influences risk
for different causes of death. Our findings suggest that
more systematic and early attention to somatic health in
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patients with SUDs, and especially in older patients
with long-lasting substance use problems, can be rele-
vant for preventing premature mortality. Men with
long-lasting SUDs are a priority group to approach with
directed preventive measures on somatic health well
before 50 years of age.
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